RET/PTC Rearrangement, Thyroid Cancer
- Laboratory
- Quest Diagnostics
- Test code
- 90473
- Specimen
- Tissue
- Fasting
- Not stated
- LOINC
- 31208-2
- Turnaround
- Set up: Daily
Laboratory assay overview
RET/PTC gene fusion is detected in 5-40% of papillary thyroid carcinomas, but has been reported at low frequency in other types of thyroid lesions. Correlation with morphologic and clinical findings is thus required. The assay tests for both RET/PTC1 and RET/PTC3 rearrangements using a reverse transcription PCR assay. The lower limit of sensitivity is approximately 2.5% mutation-bearing cells in a mixed sample, but can vary due to RNA preservation.
Quest Diagnostics population reference ranges
Quest Diagnostics calculates these statistical intervals for this specific assay and demographic group, not as universal optimal targets.
| Population | Range |
|---|---|
| RET/PTC1 | Not detected |
| RET/PTC3 | Not detected |
View complete laboratory reference notes
RET/PTC1 | Not detected RET/PTC3 | Not detected
Quest Diagnostics test directory, test code 90473